Compounds > 2,2',4,4'-tetrabromodiphenyl ether
Page last updated: 2024-08-26

2,2',4,4'-tetrabromodiphenyl ether and Non-alcoholic Fatty Liver Disease

2,2',4,4'-tetrabromodiphenyl ether has been researched along with Non-alcoholic Fatty Liver Disease in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Gerasimov, E; Logacheva, M; Naumov, V; Pilsner, JR; Sergeyev, O; Shershebnev, A; Shtratnikova, V; Suvorov, A; Wu, H; Zheludkevich, A1

Other Studies

1 other study(ies) available for 2,2',4,4'-tetrabromodiphenyl ether and Non-alcoholic Fatty Liver Disease

ArticleYear
Rat liver epigenome programing by perinatal exposure to 2,2',4'4'-tetrabromodiphenyl ether.
    Epigenomics, 2020, Volume: 12, Issue:3

    Topics: Animals; Biomarkers; Carbohydrate Metabolism; Disease Susceptibility; DNA Methylation; Environmental Pollutants; Epigenesis, Genetic; Epigenome; Halogenated Diphenyl Ethers; Lipid Metabolism; Liver; MicroRNAs; Non-alcoholic Fatty Liver Disease; Rats

2020